DK1546083T3 - Hidtil ukendte substituerede arylhexadienonsyrer og estere deraf der kan anvendes i behandlingen og forebyggelse af diabetes, dyslipidæmi og atherosklerose, farmaceutiske præparater omfattende dem og fremgangsmåder til fremstillinger af dem - Google Patents

Hidtil ukendte substituerede arylhexadienonsyrer og estere deraf der kan anvendes i behandlingen og forebyggelse af diabetes, dyslipidæmi og atherosklerose, farmaceutiske præparater omfattende dem og fremgangsmåder til fremstillinger af dem

Info

Publication number
DK1546083T3
DK1546083T3 DK03798876.3T DK03798876T DK1546083T3 DK 1546083 T3 DK1546083 T3 DK 1546083T3 DK 03798876 T DK03798876 T DK 03798876T DK 1546083 T3 DK1546083 T3 DK 1546083T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
diabetes
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
DK03798876.3T
Other languages
English (en)
Inventor
Michel Brunet
Jean-Jacques Zeiller
Gerard Ferrand
Yves Bonhomme
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1546083T3 publication Critical patent/DK1546083T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK03798876.3T 2002-10-01 2003-08-11 Hidtil ukendte substituerede arylhexadienonsyrer og estere deraf der kan anvendes i behandlingen og forebyggelse af diabetes, dyslipidæmi og atherosklerose, farmaceutiske præparater omfattende dem og fremgangsmåder til fremstillinger af dem DK1546083T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212135A FR2845087B1 (fr) 2002-10-01 2002-10-01 Nouveaux acides arylhexadienoiques substitues et leurs esters,utilisables dans le traitement et la prevention du diabete, des dyslipidemies,de l'atherosclerose, compositions pharmaceutiques les contenant et procedes de preparation
PCT/EP2003/008887 WO2004031116A1 (en) 2002-10-01 2003-08-11 Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them

Publications (1)

Publication Number Publication Date
DK1546083T3 true DK1546083T3 (da) 2010-10-04

Family

ID=31985377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03798876.3T DK1546083T3 (da) 2002-10-01 2003-08-11 Hidtil ukendte substituerede arylhexadienonsyrer og estere deraf der kan anvendes i behandlingen og forebyggelse af diabetes, dyslipidæmi og atherosklerose, farmaceutiske præparater omfattende dem og fremgangsmåder til fremstillinger af dem

Country Status (21)

Country Link
US (1) US7737176B2 (da)
EP (1) EP1546083B1 (da)
JP (1) JP4486499B2 (da)
KR (1) KR20050070026A (da)
CN (1) CN1325462C (da)
AT (1) ATE477232T1 (da)
AU (1) AU2003255412B2 (da)
BR (1) BR0314826A (da)
CA (1) CA2500649C (da)
CY (1) CY1110814T1 (da)
DE (1) DE60333765D1 (da)
DK (1) DK1546083T3 (da)
ES (1) ES2350101T3 (da)
FR (1) FR2845087B1 (da)
MX (1) MXPA05003388A (da)
PL (1) PL374489A1 (da)
PT (1) PT1546083E (da)
RU (1) RU2005113717A (da)
SI (1) SI1546083T1 (da)
WO (1) WO2004031116A1 (da)
ZA (1) ZA200503416B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013177360A (ja) 2011-08-02 2013-09-09 Sumitomo Chemical Co Ltd α−ケトアルデヒド化合物の製造方法
ES2861268T3 (es) 2011-09-20 2021-10-06 Basf Se Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
RU2051673C1 (ru) * 1992-02-07 1996-01-10 Общество с ограниченной ответственностью "ЛОШТАК" Антиатеросклеротическое и антиатерогенное средство
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
FR2869610B1 (fr) * 2004-05-03 2006-07-28 Merck Sante Soc Par Actions Si Derives de l'acide pentenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques

Also Published As

Publication number Publication date
US20060052447A1 (en) 2006-03-09
US7737176B2 (en) 2010-06-15
BR0314826A (pt) 2005-08-02
FR2845087A1 (fr) 2004-04-02
AU2003255412B2 (en) 2009-09-10
CY1110814T1 (el) 2015-06-10
DE60333765D1 (de) 2010-09-23
EP1546083A1 (en) 2005-06-29
JP4486499B2 (ja) 2010-06-23
CN1325462C (zh) 2007-07-11
CA2500649A1 (en) 2004-04-15
RU2005113717A (ru) 2006-01-20
CN1688534A (zh) 2005-10-26
AU2003255412A1 (en) 2004-04-23
ES2350101T3 (es) 2011-01-18
EP1546083B1 (en) 2010-08-11
KR20050070026A (ko) 2005-07-05
ZA200503416B (en) 2006-12-27
PT1546083E (pt) 2010-11-17
JP2006501284A (ja) 2006-01-12
CA2500649C (en) 2011-07-12
FR2845087B1 (fr) 2004-12-24
WO2004031116A1 (en) 2004-04-15
PL374489A1 (en) 2005-10-31
ATE477232T1 (de) 2010-08-15
SI1546083T1 (sl) 2010-11-30
MXPA05003388A (es) 2005-06-22

Similar Documents

Publication Publication Date Title
PH12020552187A1 (en) Pcsk9 antagonist compounds
MX2009009754A (es) Compuestos de 4-piperidinilurea como inhibidores de epoxido hidrolasa soluble.
NO20070445L (no) Pyrimidinderivater.
EA200702674A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20082108L (no) Asparaginsyrebaserte proteaseinhibitor
NO20062135L (no) Fenylderivater som PPAR-agonister
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE536172T1 (de) Ezetimibzusammensetzungen
MX2009002740A (es) Inhibidores de renina.
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
NO20071005L (no) Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer
WO2008036216A8 (en) Piperidine derivatives as renin inhibitors
NO20080554L (no) Pyrazolonderivater
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
EA200601608A1 (ru) Способ производства твёрдой фармацевтической композиции
DK1546083T3 (da) Hidtil ukendte substituerede arylhexadienonsyrer og estere deraf der kan anvendes i behandlingen og forebyggelse af diabetes, dyslipidæmi og atherosklerose, farmaceutiske præparater omfattende dem og fremgangsmåder til fremstillinger af dem
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
ZA200706705B (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
WO2007110876A3 (en) Novel sulfonanilide derivatives, pharmaceutical compositions comprising the same and process thereof
WO2006004903A3 (en) 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2005082862A3 (en) Benzimidazolyl derivatives as kinase inhibitors
WO2010067989A3 (ko) 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물